Literature DB >> 24606144

Genome engineering with targetable nucleases.

Dana Carroll1.   

Abstract

Current technology enables the production of highly specific genome modifications with excellent efficiency and specificity. Key to this capability are targetable DNA cleavage reagents and cellular DNA repair pathways. The break made by these reagents can produce localized sequence changes through inaccurate nonhomologous end joining (NHEJ), often leading to gene inactivation. Alternatively, user-provided DNA can be used as a template for repair by homologous recombination (HR), leading to the introduction of desired sequence changes. This review describes three classes of targetable cleavage reagents: zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and CRISPR/Cas RNA-guided nucleases (RGNs). As a group, these reagents have been successfully used to modify genomic sequences in a wide variety of cells and organisms, including humans. This review discusses the properties, advantages, and limitations of each system, as well as the specific considerations required for their use in different biological systems.

Entities:  

Keywords:  CRISPR/Cas; DNA repair; HR; NHEJ; TALENs; gene targeting; homologous recombination; nonhomologous end joining; zinc-finger nucleases

Mesh:

Substances:

Year:  2014        PMID: 24606144     DOI: 10.1146/annurev-biochem-060713-035418

Source DB:  PubMed          Journal:  Annu Rev Biochem        ISSN: 0066-4154            Impact factor:   23.643


  180 in total

1.  Protein engineering of Cas9 for enhanced function.

Authors:  Benjamin L Oakes; Dana C Nadler; David F Savage
Journal:  Methods Enzymol       Date:  2014       Impact factor: 1.600

2.  Synthetic CRISPR RNA-Cas9-guided genome editing in human cells.

Authors:  Meghdad Rahdar; Moira A McMahon; Thazha P Prakash; Eric E Swayze; C Frank Bennett; Don W Cleveland
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-16       Impact factor: 11.205

3.  Efficient delivery of nuclease proteins for genome editing in human stem cells and primary cells.

Authors:  Jia Liu; Thomas Gaj; Yifeng Yang; Nan Wang; Sailan Shui; Sojung Kim; Chidananda Nagamangala Kanchiswamy; Jin-Soo Kim; Carlos F Barbas
Journal:  Nat Protoc       Date:  2015-10-22       Impact factor: 13.491

4.  CRISPR-mediated Activation of Latent HIV-1 Expression.

Authors:  Prajit Limsirichai; Thomas Gaj; David V Schaffer
Journal:  Mol Ther       Date:  2015-11-26       Impact factor: 11.454

Review 5.  Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease.

Authors:  Megan D Hoban; Stuart H Orkin; Daniel E Bauer
Journal:  Blood       Date:  2016-01-12       Impact factor: 22.113

6.  Precise Correction of Disease Mutations in Induced Pluripotent Stem Cells Derived From Patients With Limb Girdle Muscular Dystrophy.

Authors:  Soeren Turan; Alfonso P Farruggio; Waracharee Srifa; John W Day; Michele P Calos
Journal:  Mol Ther       Date:  2016-02-26       Impact factor: 11.454

7.  Efficient generation of targeted large insertions by microinjection into two-cell-stage mouse embryos.

Authors:  Bin Gu; Eszter Posfai; Janet Rossant
Journal:  Nat Biotechnol       Date:  2018-06-11       Impact factor: 54.908

8.  Chemically Modified Cpf1-CRISPR RNAs Mediate Efficient Genome Editing in Mammalian Cells.

Authors:  Moira A McMahon; Thazha P Prakash; Don W Cleveland; C Frank Bennett; Meghdad Rahdar
Journal:  Mol Ther       Date:  2018-03-06       Impact factor: 11.454

9.  The history and market impact of CRISPR RNA-guided nucleases.

Authors:  Paul Bg van Erp; Gary Bloomer; Royce Wilkinson; Blake Wiedenheft
Journal:  Curr Opin Virol       Date:  2015-04-26       Impact factor: 7.090

10.  Comparison of gene activation by two TAL effectors from Xanthomonas axonopodis pv. manihotis reveals candidate host susceptibility genes in cassava.

Authors:  Megan Cohn; Robert Morbitzer; Thomas Lahaye; Brian J Staskawicz
Journal:  Mol Plant Pathol       Date:  2016-02-08       Impact factor: 5.663

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.